Robert I. Haddad
Brigham and Women's Hospital · 774 works · 40,022 citations · h-index 91
Top works
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
- Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
- Recent Advances in Head and Neck Cancer
- Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
- Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial
- Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
- Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
- Racial Survival Disparity in Head and Neck Cancer Results from Low Prevalence of Human Papillomavirus Infection in Black Oropharyngeal Cancer Patients
- Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
- Head and Neck Cancers
- Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial
- Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial
- NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018
- Head and neck cancer
- Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
- Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
- Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
- Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
- Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial